How Pseudomonas aeruginosa in cystic fibrosis lungs may change how medicines are broken down
Impact of Pseudomonas aeruginosa cytochrome P450 enzymes and secondary metabolites on drug metabolism and disposition in the cystic fibrosis patient
This project looks at whether the bacteria Pseudomonas aeruginosa in CF lungs changes how antibiotics and other drugs are broken down, which could affect treatment for people with cystic fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11224088 on NIH RePORTER |
What this research studies
If you have cystic fibrosis, this project will study whether Pseudomonas aeruginosa bacteria in your lungs change how medicines are metabolized. Researchers will examine bacterial enzymes called CYPs and chemicals the bacteria produce, using laboratory tests, bacterial samples, and human lung-related cells or specimens to measure drug breakdown. They will test effects on common antibiotics such as ciprofloxacin and whether bacterial products turn on human drug-processing enzymes like CYP1A2. The goal is to explain why some treatments may fail and to point toward ways to keep medicines working better for people with CF.
Who could benefit from this research
Good fit: People with cystic fibrosis, especially those with chronic or recent Pseudomonas aeruginosa lung infection or being treated with antibiotics like ciprofloxacin, would be most relevant to this project.
Not a fit: People without cystic fibrosis or without Pseudomonas aeruginosa lung infection are unlikely to directly benefit from this research.
Why it matters
Potential benefit: If successful, this work could lead to better drug dosing or new ways to protect antibiotics so they work more reliably for people with CF.
How similar studies have performed: Early laboratory data, including from these investigators, show bacterial enzymes can alter drug levels and bacterial metabolites can induce human drug enzymes, but applying these findings to change patient care is still new.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Lampe, Jed Noah — University of Colorado Denver
- Study coordinator: Lampe, Jed Noah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.